Prime Medicine (NASDAQ:PRME) Stock Jumps 3.5% - Here's Why

Key Points

• Prime Medicine shares rose 3.5% to about $3.62 in mid-day trading, although volume was 76% below the average session level.
• Analysts remain broadly optimistic, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $7.47, well above its current price.
• The company continues to face significant financial challenges: its latest quarter included a net loss of $0.24 per share, revenue of $1.15 million versus $4.40 million expected, and sharply negative profitability metrics.

Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report) was up 3.5% during trading on Wednesday. The company traded as high as $3.56 and last traded at $3.6240. 728,938 shares changed hands during mid-day trading, a decline of 76% from the average session volume of 2,985,511 shares. The stock had previously closed at $3.50.

Analysts Set New Price Targets

PRME has been the subject of several recent research reports. New Street Research set a $8.00 price target on Prime Medicine in a research note on Monday, June 29th. The Goldman Sachs Group set a $6.00 target price on shares of Prime Medicine in a research note on Monday, June 22nd. Citigroup reissued a "market outperform" rating on shares of Prime Medicine in a research report on Friday, September 25th. TD Cowen restated a "buy" rating on shares of Prime Medicine in a research note on Wednesday, July 8th. Finally, Jefferies Financial Group reaffirmed a "market outperform" rating on shares of Prime Medicine in a research note on Monday, September 28th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $7.47.

Prime Medicine Trading Up 8.7%

The stock has a market capitalization of $690.32 million, a P/E ratio of -3.60 and a beta of 2.37. The business's fifty day simple moving average is $3.25 and its two-hundred day simple moving average is $3.33.

Prime Medicine (NASDAQ:PRME - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.24) EPS for the quarter, meeting the consensus estimate of ($0.24). The firm had revenue of $1.15 million during the quarter, compared to analysts' expectations of $4.40 million. Prime Medicine had a negative return on equity of 188.27% and a negative net margin of 4,613.11%. On average, equities research analysts anticipate that Prime Medicine, Inc. will post -0.97 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PRME. Royal Bank of Canada boosted its stake in Prime Medicine by 89.3% in the first quarter. Royal Bank of Canada now owns 9,254 shares of the company's stock valued at $32,000 after acquiring an additional 4,365 shares during the last quarter. Glen Eagle Advisors LLC acquired a new position in shares of Prime Medicine in the 4th quarter valued at $35,000. Wealthfront Advisers LLC acquired a new position in shares of Prime Medicine in the 1st quarter valued at $36,000. Kingsview Wealth Management LLC bought a new position in shares of Prime Medicine in the 2nd quarter worth $37,000. Finally, Sequoia Financial Advisors LLC acquired a new stake in shares of Prime Medicine during the first quarter worth $41,000. 70.37% of the stock is owned by institutional investors.

Prime Medicine Company Profile

Prime Medicine, Inc NASDAQ: PRME is a biotechnology company developing genetic medicines based on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company's platform is intended to address a broad range of genetic diseases while potentially reducing some of the limitations associated with earlier gene-editing approaches.

Prime Medicine is advancing an investigational pipeline of therapies for diseases caused by genetic mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.